United States

Pharma Outlook 2030: From evolution to revolution

Wednesday May 31, 2017 1:00 PM - 2:00 PM EDT
From Healthcare & Life Sciences Institute

KPMG Healthcare & Life Sciences Institute

Event Overview

Join KPMG global thought leaders Roger van den Heuvel and Peter Gilmore, and Alison Little for KPMG’s view of the pharmaceutical industry, highlighting industry trends, funding priorities, and future-looking business archetypes.

Two seismic shifts are impacting the industry: the need to demonstrate value from therapies; and the move from treatment to prevention, diagnostics and cure, all of which is bringing in a host of new competitors.

Those pharmaceutical companies that manage to embrace the most appropriate archetypes, and master disruption, have the greatest chance to deliver real value to patients and be successful in the new, disrupted world.

To download the Pharma 2030 white paper, click here.

Roger van den Huevel

Partner, Head of Life Sciences Global Strategy

Alison Little

Principal, Life Sciences Advisory Industry Leader

Pete Gilmore

Principal, KPMG Corporate Strategy